You are here

Article Text

Article menu
Download PDFPDF
Smoking
Efficacy of bupropion in the indigenous Maori population in New Zealand
  1. S Holt1,
  2. C Timu-Parata1,
  3. S Ryder-Lewis1,
  4. M Weatherall2,
  5. R Beasley3
  1. 1P3 Research, Wellington, New Zealand
  2. 2Wellington School of Medicine and Health Sciences, Wellington, New Zealand
  3. 3Medical Research Institute of New Zealand, Wellington, New Zealand and University of Southampton, Southampton, UK
  1. Correspondence to:
    Dr S Holt
    P3 Research, Bowen Hospital, Churchill Drive, Crofton Downs, Wellington, New Zealand; shaunp3research.co.nz

Abstract

Background: Smoking rates are high in indigenous populations and contribute to their poor health. In New Zealand the indigenous Maori population has a high rate of smoking, with around 50% of adults being smokers compared with 20% of the adult European population. A study was undertaken to determine whether bupropion is effective in the treatment of smoking cessation in the indigenous Maori population in New Zealand.

Methods: A randomised, placebo controlled, double blind, parallel group study was performed in 134 Maori smokers aged 16–70 years who smoked more than 10 cigarettes per day. The main outcome measures were continued abstinence from smoking at 3 and 12 months.

Results: At each time point continued abstinence was better for the subjects allocated to bupropion, with a risk ratio for abstinence over all time points of 2.44 (95% CI 1.22 to 4.88). The rates of continued abstinence in the bupropion and placebo groups at 3 months were 44.3% and 17.4%, respectively, with a risk ratio of 2.54 (95% CI 1.30 to 5.00). The corresponding figures at 12 months were 21.6% and 10.9%, respectively, with a risk ratio of 1.99 (95% CI 0.79 to 5.00).

Conclusion: Bupropion is an effective treatment for smoking cessation in the indigenous Maori population in New Zealand.

  • smoking cessation
  • bupropion
  • Maori

https://doi.org/10.1136/thx.2004.030239

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • This study was supported by a research grant from GlaxoSmithKline to P3 Research.

    • Conflict of interest: P3 Research, the Wellington School of Medicine and Health Sciences, and the Medical Research Institute of New Zealand have all received research grants from GlaxoSmithKline and Novartis. SH and RB have received fees for consulting and reimbursement for attending symposia from GlaxoSmithKline and Novartis.

    • SH and RB designed the study and wrote the manuscript with help from the other authors; SH coordinated the study, collected data with CT-P and SR-L; MW undertook the data analysis. SH will act as guarantor.